arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Trevi Therapeutics, Inc.

TRVI
$14.45 ▼ -0.79 (-5.18%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
37
Health
Weak
Neutral
auto_awesome

Analytical Summary

Trevi Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.3B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -6.4%
FCF / Share $-0.11
Trailing P/E
Price / Book 6.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-17.80M
↓ -44.7%
FCF / Share Free cash flow per share
$-0.11
↑ +2.8%

Health Breakdown

Returns
26
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 35 quarters